Does oxaliplatin benefit come with an age limit in patients with stage II or III colorectal cancer (CRC)?

New data from a population-based cohort show that adding oxaliplatin chemotherapy to fluoropyrimidine in the adjuvant setting significantly improved survival in patients with stage III CRC up to age 70 but not those older than age 70. The analysis also revealed that the drug did not improve survival in those with stage II disease, regardless of patients’ age.

“The findings suggest that oxaliplatin may benefit patients aged 70 years or younger with stage III colorectal cancer, while its use in patients aged older than 70 years and those with stage II disease warrants reconsideration,” according to the study authors, led by Jun Woo Bong, MD, PhD, of Korea University Guro Hospital in S

See Full Page